Oppenheimer & CO Inc Myriad Genetics Inc Transaction History
Oppenheimer & CO Inc
- $6.18 Billion
- Q2 2024
A detailed history of Oppenheimer & CO Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Oppenheimer & CO Inc holds 18,066 shares of MYGN stock, worth $478,026. This represents 0.01% of its overall portfolio holdings.
Number of Shares
18,066
Previous 15,188
18.95%
Holding current value
$478,026
Previous $323,000
36.53%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding MYGN
# of Institutions
232Shares Held
92.6MCall Options Held
117KPut Options Held
113K-
Black Rock Inc. New York, NY15.2MShares$401 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$266 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA8.26MShares$219 Million0.04% of portfolio
-
Camber Capital Management LP Boston, MA5.5MShares$146 Million3.72% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.4MShares$116 Million0.05% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $2.13B
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...